Related Experiment Video
Updated: Sep 14, 2025

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
The effect of PDLIM7 on cell proliferation, migration, and drug sensitivity in clear cell renal cell carcinoma
Chong Shen1, Jian Zhuo2, Jianying Wang3
1Yangzhou Third People's Hospital, Yangzhou, China. Shenchong66@163.com.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cancer primarily originating from renal tubular epithelial cells. The absence of effective treatments has contributed to its poor prognosis. PDLIM7 is a protein containing PDZ and LIM structural domains, which performs varied functions through interactions with different proteins. To elucidate the role of PDLIM7 in ccRCC, we aimed to investigate its potential functions in relation to drug sensitivity. We analyzed multiple databases to assess the relationship between PDLIM7 expression and clinicopathological features, and conducted survival prognosis analysis. The expression level of PDLIM7 was validated through Western blotting and immunohistochemistry (IHC). We determined the effects and mechanisms of PDLIM7 on cancer cell proliferation, migration, and invasion through cloning assays, scratch assays, and Transwell assays. The functions and potential mechanisms of action of PDLIM7 were analyzed using gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses. Its relationship with drug sensitivity was predicted utilizing the CellMiner database. Our study demonstrated that elevated PDLIM7 expression in ccRCC tissues and cell lines is significantly associated with the prognosis of patients with ccRCC. The knockdown of PDLIM7 markedly reduced the activity of ccRCC cells. KEGG and GO functional enrichment analyses indicated that PDLIM7 is implicated in various biological functions and signaling pathways. Higher levels of PDLIM7 are associated with increased sensitivity to a range of therapeutic agents. In conclusion, PDLIM7 is highly expressed in ccRCC and functions as an oncogene; its knockdown significantly inhibits the activity of ccRCC cells. PDLIM7 may serve as a prognostic marker for ccRCC and represents a potential therapeutic target.
Insights
PDLIM7 is highly expressed in clear cell renal cell carcinoma (ccRCC) and promotes cancer cell activity. Targeting PDLIM7 may improve ccRCC prognosis and drug sensitivity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Clear cell renal cell carcinoma (ccRCC) has a poor prognosis due to limited treatment options.
- PDLIM7, a protein with PDZ and LIM domains, has diverse cellular functions.
- The role of PDLIM7 in ccRCC and its impact on drug sensitivity remain largely unexplored.
Purpose of the Study:
- To investigate the role of PDLIM7 in ccRCC progression and its association with patient prognosis.
- To explore the potential of PDLIM7 as a therapeutic target and a predictor of drug sensitivity in ccRCC.
Main Methods:
- Analysis of PDLIM7 expression in ccRCC tissues and cell lines using Western blotting and IHC.
- Functional assays (cloning, scratch, Transwell) to assess PDLIM7's effect on ccRCC cell proliferation, migration, and invasion.
- Bioinformatic analyses (GO, KEGG, CellMiner) to determine PDLIM7's functions, pathways, and drug sensitivity correlations.
Main Results:
- Elevated PDLIM7 expression in ccRCC tissues and cell lines correlates significantly with poorer patient prognosis.
- PDLIM7 knockdown markedly reduced ccRCC cell proliferation, migration, and invasion.
- PDLIM7 is implicated in various biological functions and signaling pathways, and higher PDLIM7 levels predict increased sensitivity to certain therapeutic agents.
Conclusions:
- PDLIM7 is overexpressed in ccRCC, acting as an oncogene that promotes tumor progression.
- PDLIM7 serves as a potential prognostic biomarker and a promising therapeutic target for ccRCC.
- Targeting PDLIM7 could enhance the efficacy of ccRCC treatments and improve patient outcomes.

